explore -WSS

explore

author：leisure time 2025-09-29 13:31:24 - browse：8557

insulin biosimilar — Last week, the FDA released a trio of guidelines clarifying the way they plan to evaluate devices that go through the 510(k) pathway. Jacquelyn Martin/AP

Five years after promising to fix a flawed regulatory pathway widely used by medical device manufacturers, the Food and Drug Administration has issued new guidelines to improve its so-called 510(k) program that has long been lambasted for letting risky devices fall through the cracks.

Most medical device companies do not have to test their products on people in order to secure clearance from the FDA — they simply have to show they’re “substantially equivalent” to devices already on the market, called “predicates.” This process is the 510(k) pathway, and accounts for the vast majority of new medical devices launched on the market each year. Devices cleared through this pathway include X-ray machines, muscle stimulators, and wheelchairs.

Last week, the FDA released a trio of guidelines clarifying the way it plans to evaluate devices that go through the 510(k) pathway. The agency is asking manufacturers to avoid predicate devices that were recalled due to a “design-related” issue or have “unmitigated” safety concerns. Manufacturers should submit flow charts explaining why they chose their predicate device. If they have to choose one with a recall history or safety issues, they should explain how the new device addresses those problems. The FDA may also ask the manufacturer for clinical data in this case.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： George Santos makes 1st court appearance after pleading not guilty to 13 counts
Next article： CDC marks new Covid

explore

WSS

With psoriasis trial ahead, Alumis raises $259 million

Experimental asthma app from Apple and Anthem shows promise

Weight loss drugs should be covered by insurers, AMA says

Precocious puberty in girls comes with mental health risks

The problem with charging patients to message their doctors

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

focus

explore

hotspot

Drug repurposing or repositioning? The language matters

In his State of the Union, Biden takes clear aim at 'Big Pharma'

Psychedelics group wrestles with new pharma identity

Medicare’s new pay boost for primary care is angering specialists

In age of alternative facts, a scholarly course on calling out crap

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

Sports medicine is finally prioritizing gender equality

FDA reorg will put new emphasis on investigations, sources say

Virginia high school admissions case could be legal follow

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

entertainment

Air quality improving but still lags in Black, Hispanic communities

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

White House drug czar issues call for 'recovery

Just how do doctors, lawmakers, and the public define abortion?

A deep dive into Applied Therapeutics’ data, and questions on Cassava

Type 2 diabetes prevention programs work at large scale: study

focus

Wikipedia

explore

focus